Committee approves allowing cannabis oil in hospitals and creates study work group; report due Nov. 1, 2026
February 19, 2026 | 2026 Legislature VA, Virginia
This article was created by AI summarizing key points discussed. AI makes mistakes, so for full details and context, please refer to the video of the full meeting. Please report any errors so we can fix them. Report an error »
Senator Veil presented a substitute to SB 332 that would allow cannabis oil to be used in hospitals and establish a work group to evaluate the possibility of allowing additional cannabis products in the future.
"What this does is very simple. It does allow for the use of oil cannabis in hospitals," Veil said, adding that oil is already permitted in nursing homes and other clinical settings. The substitute sets a report deadline of Nov. 1, 2026, to return findings and recommendations to the General Assembly.
Veil told the committee that hospital stakeholders, including the Medical Society of Virginia, preferred narrow oil-focused language to avoid conflicts with the Federal Controlled Substances Act and to protect federal funding streams such as Medicaid and Medicare.
Committee members asked whether the substitute would allow gummies, tinctures or vaping products; Veil said the work group would study those options and that the current language tracks the criminal code’s treatment of oil. The committee voted to report the substitute by a recorded vote of 19 to 1.
What this does: the substitute permits cannabis oil in hospitals immediately and directs a work group to examine other product forms and report back to the legislature; it does not expand use of non-oil products without further action.
What’s next: the work group will study product definitions and federal-compatibility concerns and deliver a report by 11/01/2026; any broader change would require further legislative or regulatory action.
"What this does is very simple. It does allow for the use of oil cannabis in hospitals," Veil said, adding that oil is already permitted in nursing homes and other clinical settings. The substitute sets a report deadline of Nov. 1, 2026, to return findings and recommendations to the General Assembly.
Veil told the committee that hospital stakeholders, including the Medical Society of Virginia, preferred narrow oil-focused language to avoid conflicts with the Federal Controlled Substances Act and to protect federal funding streams such as Medicaid and Medicare.
Committee members asked whether the substitute would allow gummies, tinctures or vaping products; Veil said the work group would study those options and that the current language tracks the criminal code’s treatment of oil. The committee voted to report the substitute by a recorded vote of 19 to 1.
What this does: the substitute permits cannabis oil in hospitals immediately and directs a work group to examine other product forms and report back to the legislature; it does not expand use of non-oil products without further action.
What’s next: the work group will study product definitions and federal-compatibility concerns and deliver a report by 11/01/2026; any broader change would require further legislative or regulatory action.
Don't Miss a Word: See the Full Meeting!
Go beyond summaries. Unlock every video, transcript, and key insight with a Founder Membership.
✓
Get instant access to full meeting videos
✓
Search and clip any phrase from complete transcripts
✓
Receive AI-powered summaries & custom alerts
✓
Enjoy lifetime, unrestricted access to government data
30-day money-back guarantee
